Associate Project Manager
Dimitris Poulimeneas is a Registered Dietitian - Nutritionist, with a Master’s in Public Health and a Doctorate in Applied Nutrition and Dietetics. His research primarily focuses in Obesity Management, and Paediatric Nutrition, with his research output including more than 35 publications in international peer-reviewed journals.
Dr Poulimeneas has worked as a Researcher in several EU funded research programs. He is currently a Lecturer of Dietetics at the Department of Nutrition and Dietetics of the University of the Peloponnese, and joined CLEO as a Project Manager.
VACCELERATE - European Corona Vaccine Trial Accelerator Platform
VACCELERATE aims to accelerate phase 2 & 3 COVID-19 vaccine trials. It is part of the European Commission “HERA incubator” program and it involves 29 partners both from EU-member states and EU-associated countries. VACCELERATE brings together different stakeholders involved in vaccine development across the EU to develop a platform for trial design and conduct. Its end goal is to develop a vaccine clinical trial network for the COVID-19 pandemic as well as to serve as point of reference for future emerging infectious diseases by playing a pivotal role in strengthening the vaccine development capacities of Europe.
VACCELERATE is 3-year project. It started in February 2021 and will terminate in February 2024. It has received funding from the European Union's Horizon 2020 programme (Grant Agreement no. 101037867).
CLEO is the National Coordinator for Greece, thereby acting as an ambassador of VACCELERATE and serving as the country’s point of contact. In this role, CLEO maps clinical trial sites and laboratories in Greece, while also adapting all VACCELERATE activities to national requirements and identifying the needs for education and capacity building across Greek vaccine trial sites.
CLEO is also the lead partner for the capacity mapping analysis of pediatric vaccine clinical trial sites across Europe. The main objectives are to map and analyze the capacity of these sites, collect and analyze past performance and define minimum quality standards with a focus on the standardization and harmonization of pediatric COVID-19 vaccine research, in order to develop or inform pediatric-specific vaccination programs future.
CLEO is also a co-lead and contributor to VACCELERATE research activities focused on understanding volunteer COVID-19 vaccine trial participation, especially among under-represented and hard-to-reach groups across Europe and EU-associated countries.
Relavant Links:
Clinical trial sites interested in conducting COVID-19 vaccine studies can register to the EUVAP Platform, https://www.euvap.eu/
For individuals interested in signing up to upcoming COVID-19 vaccination studies, https://www.vaccelerate.eu/volunteer-registry/index.html
Contact us: This email address is being protected from spambots. You need JavaScript enabled to view it.
Read more about VACCELERATE, https://vaccelerate.eu/.
General
The internet site http://www.cleoresearch.org (hereinafter mentioned as the “site” or “website”, with the aforementioned terms having the same meaning) aims at personal information of its visitors – users (hereinafter mentioned as its “users”)
The Legal Notice and Terms of Use, as modified each time by the Non Profit Company “Collaborative Center for Clinical Epidemiology and Outcomes Research” with the distinctive title “CLEO” (hereinafter mentioned as “CLEO”) set out the terms for the use of the website.
Please read carefully the Legal Notice and the Terms of Use.
The use and access of the website is subject to the below terms and conditions, as well as to the applicable legislation. The connection and the access to the webpage suggests the understanding and the full and unconditional acceptance of all the general terms and conditions for the use of the website.
In case you do not agree with some of the terms and conditions, please leave this webpage immediately.
This website is published by CLEO, registered in GEMI 132542701000/24.11.2014, with a registered seat in Athens, at Chatzigianni Mexi 5.
Manager: Georgia Kourlaba
5, Chatzigianni Mexi
115 28 – Athens, Greece
Land Line: +30 210 777 7363
Email: info [at] cleoresearch.org
Legal Notice
This website includes general information about CLEO. CLEO retains the right to change its content without prior notice. Neither this website nor some or all of its components intend to give advice or advertise the services rendered by CLEO. No section of this site may be deemed by users, directly or indirectly, as guidance or advice for action or omission. The users should act at their own will, without any responsibility undertaken by CLEO. This website may include information or reference to recent research results or activities of CLEO. Any such information is given for informative purposes only and users should not depend on it or reproduce it or republish it without the prior, express and written consent from CLEO.
Intellectual Property
This webpage in its entirety (apart from the data which are explicitly mentioned as Intellectual Property of third parties) is considered as Intellectual Property of CLEO, subject to domestic, international and EU provisions protecting Intellectual Property.
Any data belonging to third parties is included in the webpage in good faith and exclusively for informative purposes. They will be removed immediately upon request from the beneficiaries.
It is explicitly forbidden to reproduce, copy, use, redistribute, amend, adjust, incorporate, republish, translate, commercially use or transmit in any way or format (electronically or in hard copy) in total or in part the information included in the site or distribute registered Trade Marks appearing in the website without the prior written consent and permission of CLEO, with the exception of the below provision applicable to research or educational purposes.
Moreover, any information included in the site may not be used in public media without the prior written consent of CLEO.
License of use
CLEO encourages the use of the website for educational or research purposes and personal information. The reproduction or storage of data included in the website is allowed solely for educational or research purposes, with the sole condition of reference of the website where the information was retrieved and the names of the creators (if these names appear in the website), taking into account the non-violation of Intellectual or Industrial Property rights.
However, some of the files or data may be Intellectual Property of third parties and may not be used without the latter’s prior consent (which may be included in the relevant section of the webpage). The users agree and accept unconditionally the above statement.
Disclaimers and Internet Liability Limitations
CLEO makes all necessary effort to ensure that its content and the information included in the website is characterized by accuracy, clarity, correctness, completeness, scientific diligence, and sufficiency, is updated and always available.
Any possible efforts are also made to ensure good network operation, but it cannot be guaranteed that the present webpage or the servers used to make it available to the users are free of viruses and the webpages, the services, the options or their results are accurate, complete and available at all times.
Every user has the exclusive responsibility to ensure through the use of the proper anti-virus software the protection of his hardware and his records and files from viruses or malware – applications and the proper management of any detected virus. In any case, the user is subject to the total cost for the repair, maintenance or fix of his computer and operating system to its previous condition.
Links
CLEO, in any case, does not have any responsibility for the content and the products or services offered in other websites or are linked in any way with the webpage.
Links are used exclusively to make the use of the webpage by the users easier, whereas the webpages provided are subject to respective terms and conditions applicable in each case. The use of the links does not mean that CLEO approves or endorses the content of these websites and it is underlined that CLEO does not bear any responsibility for their content and any damage incurred from their use, since the user accesses them at his own responsibility.
CLEO should not be held responsible for the provisions governing personal data for users applied in these websites.
Protection of Personal Data policy
- Data we collect
During your electronic communication with CLEO, the latter may collect your personal information, including your name and email address.
- Why we collect
Your personal data are used solely for the dispatch of informative material and the updating of the users with respect to CLEO activities. Moreover, they are used so that CLEO can contact back the users or answer their requests.
- To whom we may communicate your data
The data collected by the users are not disclosed to any third party and are not published in any way or are not in any way exploited.
- What are your rights with respect to personal data
According to articles 11-13 Law 2472/1997, you have the right to access and the right to deny the use of your personal data. In the event that you wish to exercise these rights, please send an email to This email address is being protected from spambots. You need JavaScript enabled to view it. or a mail at the below postal address:
Collaborative Center for Clinical Epidemiology and Outcomes Research, Non-profit Company 5, Chatzigianni Mexi 115 28 – Athens,
Greece info[at]cleoresearch.org
Applicable Law and Jurisdiction
This webpage and the aforesaid terms of use are subject to Greek Law.
For any dispute related to the use, the execution, the interpretation or the content of the website, Greek Law is solely applicable and the Courts of Athens are solely competent to resolve the said dispute.
Data on Hospital Infections in Greece
Hospital-acquired infections are among the most common complications of hospitalization. Their consequences are significant, both for patients and for the Greek health system, as they extend patient stays, increase hospitalization costs tremendously, and may result in death.
According to available data, over 10% of hospitalized patients in Greece acquire healthcare-associated infections, resulting in over 3,000 deaths per year. Additionally, hospital-acquired infections increase the length of hospital stays and burden the Greek health system with costs of more than 1.2 billion euros annually.
According to the literature, however, hospital-acquired infections can be reduced significantly or even avoided altogether.
Action taken by CLEO to control and prevent hospital infections
From July 2012 through December 2015, CLEO’s work made waves in the sector of hospital infection prevention and control, resulting in a higher level of hospital care for the pediatric patients at the “Aghia Sophia” and the “Panagiotis and Aglaia Kyriakou” hospitals. CLEO’s activities focused on:
The results of these activities are encouraging, and have been published in symposia and internationally renowned scientific journals. This work has also garnered popular media attention.
RedCap is a secure, reliable and flexible web application for building and managing online databases. It is specifically adapted for the support of electronic recording of data in research studies. It allows the simultaneous registration of data from a lot of individuals from different centers. Each center has exclusive access to its own data. RedCap provides the ability to export data in common data analysis packages such as Microsoft Excel, SPSS, STATA, R, SAS.
Data entry in RedCap from our partners can be performed after authentication password.
Sign in here
